CompletedNot Applicable

Biomarkers in Autosomal Dominant Cerebellar Ataxia

France102 participantsStarted 2011-11

Plain-language summary

Autosomal dominant cerebellar ataxias (ADCA) are a group of neurodegenerative disorders that are clinically and genetically various. BIOSCA study aims to identify markers of the metabolism (energy production inside the cells) in the blood and the brain of ADCA 1,2,3 and 7 patients and control subjects, in the perspective of future therapeutic trials.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria : * More than 18 years of age * Ability to tolerate MRI * Positive genetic test to SCA1, 2, 3 or 7 * Coverage by social insurance * Written informed consent must be obtained from the subject Exclusion criteria : * Less than 18 years of age * Concomitant significant neurological disorder * Unsuitability for MRI, e.g. claustrophobia, metal implants * History of significant head injury * Unability to receive an informed explanation about the protocol * Unability to complete the protocol * Non coverage by social insurance * No written informed consent obtained

What they're measuring

metabolic biomarkers of SCA

Timeframe: 12 months or 24 months

Trial details

NCT IDNCT01470729

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2015-12

View on ClinicalTrials.gov More Spinocerebellar Ataxia Type 1 trials